Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMTBGW8)

Drug Name
Vardenafil Drug Info
Synonyms
VDN; Levitra (TN); VARDENAFIL, LEVITRA; Vardenafil (INN); 1-((3-(3,4-Dihydro-5-methyl-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine; 2-(2-Ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3H-imidazo(5,1-f)(1,2,4)triazin-4-one; 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one; 2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE; 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4-ol
Therapeutic ClassAntiimpotence Agents
Cross-matching ID
PubChem CID
135400189
ChEBI ID
CHEMBL1520
CAS Number
CAS 224785-90-4
TTD Drug ID
D0C9SY
VARIDT Drug ID
DR00169
INTEDE Drug ID
DR1673
ACDINA Drug ID
D00721

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Propanoate metabolism 2.27 0.00e+0 30/34 (88.24%) LDHB;PCCA;ALDH6A1;...
Lysine degradation 2.05 0.00e+0 51/63 (80.95%) PLOD2;ALDH2;DLST;...
Glycolysis / Gluconeogenesis 1.98 8.74e-3 56/67 (83.58%) ENO2;LDHB;PGAM1;...
Primary bile acid biosynthesis 1.92 9.83e-3 15/17 (88.24%) AMACR;HSD17B4;CYP39A1;...
Thyroid hormone synthesis 1.86 1.31e-2 66/75 (88%) PRKCB;GNAS;FXYD2;...
Pyruvate metabolism 1.82 2.40e-2 41/47 (87.23%) LDHB;ALDH2;PDHA1;...
Valine, leucine and isoleucine degradation 1.80 2.62e-2 42/48 (87.5%) ALDH2;PCCA;ACADSB;...
Tryptophan metabolism 1.80 2.29e-2 35/42 (83.33%) CYP1B1;ALDH2;AOX1;...
cGMP-PKG signaling pathway 1.79 2.48e-2 145/167 (86.83%) MEF2C;GNAI1;MYLK;...
Carbohydrate digestion and absorption 1.79 2.36e-2 37/47 (78.72%) PRKCB;PIK3R1;FXYD2;...
Parathyroid hormone synthesis, secretion and action 1.76 2.98e-2 98/106 (92.45%) MEF2C;GNAI1;PRKCB;...
Insulin secretion 1.76 3.06e-2 75/86 (87.21%) PRKCB;GNAS;FXYD2;...
beta-Alanine metabolism 1.74 3.63e-2 25/30 (83.33%) ALDH2;ALDH1B1;ALDH6A1;...
Fatty acid degradation 1.73 3.37e-2 40/43 (93.02%) ALDH2;ACADSB;ALDH1B1;...
Cholinergic synapse 1.73 3.23e-2 99/113 (87.61%) GNAI1;PRKCB;PIK3R1;...
Long-term depression 1.71 3.60e-2 55/60 (91.67%) GNAI1;LYN;PRKCB;...
Morphine addiction 1.70 3.70e-2 80/91 (87.91%) GNAI1;PRKCB;GNAS;...
Other types of O-glycan biosynthesis 1.68 3.86e-2 29/47 (61.7%) ST6GAL1;GALNT14;OGT;...
GnRH secretion 1.67 4.41e-2 60/64 (93.75%) PRKCB;PIK3R1;SPP1;...
Non-homologous end-joining 1.66 4.39e-2 11/13 (84.62%) DNTT;PRKDC;XRCC5;...
Proteasome -1.75 3.77e-2 44/46 (95.65%) PSMD2;PSMB10;PSMD3;...
Cytosolic DNA-sensing pathway -1.85 1.70e-2 52/63 (82.54%) IKBKG;POLR3E;POLR1C;...
Staphylococcus aureus infection -1.85 2.01e-2 72/95 (75.79%) HLA-DQA1;FCGR2C;DEFA4;...
SNARE interactions in vesicular transport -1.86 3.02e-2 19/33 (57.58%) STX18;SNAP23;BET1L;...
Mineral absorption -1.89 3.02e-2 48/60 (80%) SLC34A2;HMOX2;HMOX1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 6.66uM 72H
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H